ENDED study
What does the study involve?
Down's syndrome is the most common intellectual disability with a genetic origin, affecting more than 5 million people worldwide. Medical procedures have substantially increased the life expectancy of people with Down's syndrome. However, cognitive and behavioural deficits have a strong impact on their daily activities and there is no approved treatment to improve these deficits in individuals with Down's syndrome. A new molecule has been developed , known as AEF0217, which has a very new mechanism of action, modulating the receptors in the brain that are related to the effects of cannabis (cannabinoid receptors). Studies in animal models that reproduce the cognitive deficits of people with Down's syndrome have shown that AEF0217 is effective in improving cognitive performance. However, no studies have yet been carried out in humans to demonstrate its tolerability or efficacy. In this project we will study, for the first time in healthy volunteers, whether the AEF0217 molecule is safe and well tolerated.
The study is divided into three parts (Part 1: Single Rising Dose; Part 2: Multiple Rising Doses; and Part 3: Interaction with food). 68 volunteers will be needed to carry out the three parts of the study. If you take part in one part of the study you will not be able to take part in another. Depending on the part of the study, it will last from 2 to 10 weeks.
If you are selected according to the criteria of the study protocol, you will be scheduled for a day at the IMIM Clinical Research Unit (CRU). A physical examination will be carried out, details of your medical history will be collected, your vital signs will be recorded and blood tests will be performed. A negative PCR test for SARS-COV-2 from the 72 hours prior to admission to the CRU will also be requested. Once selected, you may be treated with either the AEF0217 molecule or a placebo (a product similar to the one we studied, but without any active substance), on a random basis (like flipping a coin). You will have to stay in the CRU for at least two nights. You will also have to come in several times over the duration of the study for follow-up visits.
Inclusion criteria:
Dr. Aiguader, 88, 08003 Barcelona
See location on Google Maps
Phone: 93 316 04 00 · Fax: 93 316 04 10
info(ELIMINAR)@researchmar.net